Anti-angiogenic therapies in brain metastases - PubMed (original) (raw)

Review

Anti-angiogenic therapies in brain metastases

Anna S Berghoff et al. Memo. 2018.

Abstract

Brain metastases are a major challenge in modern oncology, as treatment options upon the diagnosis of symptomatic brain metastases are limited. Neo-angiogenesis was identified as a hallmark of brain metastasis development and inhibition using anti-angiogenic therapy might therefore be an experimental promising preventive as well as therapeutic approach. The current review will summarize the current available data on the efficacy of neo-angiogenic therapies in patients with brain metastases.

Keywords: Asymptomatic; Bevacizumab; CNS metastases; Symptomatic; Systemic treatment.

PubMed Disclaimer

Conflict of interest statement

A.S. Berghoff and M. Preusser have received travel support and honoraria from Roche.

Similar articles

• Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS metastases: the Road less Travelled.
  Veytsman I, Aragon-Ching JB, Swain SM. Veytsman I, et al. Curr Mol Pharmacol. 2013 Jan 8. Online ahead of print. Curr Mol Pharmacol. 2013. PMID: 23302002
• Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.
  Bridgeman VL, Vermeulen PB, Foo S, Bilecz A, Daley F, Kostaras E, Nathan MR, Wan E, Frentzas S, Schweiger T, Hegedus B, Hoetzenecker K, Renyi-Vamos F, Kuczynski EA, Vasudev NS, Larkin J, Gore M, Dvorak HF, Paku S, Kerbel RS, Dome B, Reynolds AR. Bridgeman VL, et al. J Pathol. 2017 Feb;241(3):362-374. doi: 10.1002/path.4845. Epub 2016 Dec 29. J Pathol. 2017. PMID: 27859259 Free PMC article.
• Targeting angiogenesis for treatment of NSCLC brain metastases.
  Schettino C, Bareschino MA, Rossi A, Maione P, Sacco PC, Colantuoni G, Rossi E, Gridelli C. Schettino C, et al. Curr Cancer Drug Targets. 2012 Mar;12(3):289-99. doi: 10.2174/156800912799277476. Curr Cancer Drug Targets. 2012. PMID: 22229249 Review.
• Novel anti-angiogenic therapies for malignant gliomas.
  Norden AD, Drappatz J, Wen PY. Norden AD, et al. Lancet Neurol. 2008 Dec;7(12):1152-60. doi: 10.1016/S1474-4422(08)70260-6. Lancet Neurol. 2008. PMID: 19007739 Review.
• Trends and Challenges in Tumor Anti-Angiogenic Therapies.
  Jászai J, Schmidt MHH. Jászai J, et al. Cells. 2019 Sep 18;8(9):1102. doi: 10.3390/cells8091102. Cells. 2019. PMID: 31540455 Free PMC article. Review.

Cited by

• The origin of brain malignancies at the blood-brain barrier.
  McDonald B, Barth K, Schmidt MHH. McDonald B, et al. Cell Mol Life Sci. 2023 Sep 9;80(10):282. doi: 10.1007/s00018-023-04934-1. Cell Mol Life Sci. 2023. PMID: 37688612 Free PMC article. Review.
• Imaging angiogenesis in an intracerebrally induced model of brain macrometastasis using αv β3 -targeted iron oxide microparticles.
  Buck J, Perez-Balderas F, Zarghami N, Johanssen V, Khrapitchev AA, Larkin JR, Sibson NR. Buck J, et al. NMR Biomed. 2023 Apr 10;36(9):e4948. doi: 10.1002/nbm.4948. Online ahead of print. NMR Biomed. 2023. PMID: 37038086 Free PMC article.
• The association between graded prognostic assessment and the prognosis of brain metastases after whole brain radiotherapy: a meta-analysis.
  Geng X, Kou C, Wang J. Geng X, et al. Front Oncol. 2024 Jan 9;13:1322262. doi: 10.3389/fonc.2023.1322262. eCollection 2023. Front Oncol. 2024. PMID: 38264750 Free PMC article.
• Continuous Low-Dose Apatinib Combined With WBRT Significantly Reduces Peritumoral Edema and Enhances the Efficacy of Symptomatic Multiple Brain Metastases in NSCLC.
  Ren Y, Wang SB, Zhou L, Liu SQ, Du LY, Li T, Jiang MQ, Lei KJ, Tan BX, Jia YM. Ren Y, et al. Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211011968. doi: 10.1177/15330338211011968. Technol Cancer Res Treat. 2021. PMID: 33955301 Free PMC article.
• The Evolving Modern Management of Brain Metastasis.
  Fecci PE, Champion CD, Hoj J, McKernan CM, Goodwin CR, Kirkpatrick JP, Anders CK, Pendergast AM, Sampson JH. Fecci PE, et al. Clin Cancer Res. 2019 Nov 15;25(22):6570-6580. doi: 10.1158/1078-0432.CCR-18-1624. Epub 2019 Jun 18. Clin Cancer Res. 2019. PMID: 31213459 Free PMC article. Review.

References

1. 1. Barnholtz-Sloan JS, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22(14):2865–2872. doi: 10.1200/JCO.2004.12.149. - DOI - PubMed
2. 1. Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. J Neurooncol. 2005;75(1):5–14. doi: 10.1007/s11060-004-8093-6. - DOI - PubMed
3. 1. Berghoff AS, et al. Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers. ESMO Open. 2016;1(2):e000024. doi: 10.1136/esmoopen-2015-000024. - DOI - PMC - PubMed
4. 1. Soffietti R, et al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO) Neuro Oncol. 2017;19(2):162–174. doi: 10.1093/neuonc/now241. - DOI - PMC - PubMed
5. 1. Preusser M, et al. Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. Eur J Cancer. 2012;48(18):3439–3447. doi: 10.1016/j.ejca.2012.07.002. - DOI - PubMed

Publication types

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database
  • scite Smart Citations